AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9670603 — intervention group
Group type: COMPARATOR
Intervention: Alprazolam (placebo-controlled)
Number of subjects: 9
Study 7873699 — intervention group
Group type: EXPERIMENTAL
Intervention: CS+ (sherbet sweet/white noise) paired with epinephrine injection (0.2 mg subcutaneously)
Number of subjects: 0
Study 7873699 — intervention group
Group type: COMPARATOR
Intervention: CS- (herbal sweet/auditory stimulus)
Number of subjects: 0
Study 3068191 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple logistic function model for preoperative assessment
Number of subjects: 8630
Study 3068191 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B, 2590 patients)
Number of subjects: 8630
Study 31084532 — intervention group
Group type: EXPERIMENTAL
Intervention: Type II resin‐modified glass ionomer (RMGI)
Number of subjects: 75
Study 31084532 — intervention group
Group type: COMPARATOR
Intervention: Control group (no box elevation procedure)
Number of subjects: 75
Study 31084532 — intervention group
Group type: EXPERIMENTAL
Intervention: Type II glass ionomer (GI)
Number of subjects: 75
Study 31084532 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin‐based composite (RBC)
Number of subjects: 75
Study 31084532 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulk‐fill (BF) resin‐based composite
Number of subjects: 75
Study 31084532 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (RMGI, RBC, BF)
Number of subjects: 75
Study 30526194 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term androgen deprivation (LTAD; 28 months)
Number of subjects: 1520
Study 30526194 — intervention group
Group type: COMPARATOR
Intervention: Short-term androgen deprivation (AD; 4 months)
Number of subjects: 1520
Study 28164268 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraclavicular block with 20 ml of 0.375% ropivacaine
Number of subjects: 49
Study 28164268 — intervention group
Group type: COMPARATOR
Intervention: Interscalene block with 20 ml of 0.375% ropivacaine
Number of subjects: 49
Study 28164268 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraclavicular block
Number of subjects: 49
Study 28164268 — intervention group
Group type: COMPARATOR
Intervention: Interscalene block
Number of subjects: 49
Study 25979871 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking reduction (biologically validated prolonged reducers)
Number of subjects: 2066
Study 25979871 — intervention group
Group type: COMPARATOR
Intervention: Continuing smokers
Number of subjects: 2066
Study 22556209 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily feeding supplementation with a multispecies probiotic (1 g per day)
Number of subjects: 150
Study 22556209 — intervention group
Group type: COMPARATOR
Intervention: Regular feedings with nothing added (control group)
Number of subjects: 150
Study 22556209 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined risk of NEC or death for the study group
Number of subjects: 150
Study 21632815 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (10 μg, single sc injection)
Number of subjects: 8
Study 21632815 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 8
Study 18823693 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate endocrine treatment (ET) consisting of a depot luteinising hormone-releasing hormone (LHRH) agonist and 1 month of an anti-androgen or surgical castration.
Number of subjects: 234
Study 18823693 — intervention group
Group type: COMPARATOR
Intervention: Delayed endocrine treatment (ET) consisting of a depot luteinising hormone-releasing hormone (LHRH) agonist and 1 month of an anti-androgen or surgical castration.
Number of subjects: 234
Study 18823693 — intervention group
Group type: COMPARATOR
Intervention: Delayed endocrine treatment (ET)
Number of subjects: 234
Study 18823693 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate endocrine treatment (ET)
Number of subjects: 234
Study 18823693 — intervention group
Group type: EXPERIMENTAL
Intervention: Both immediate and delayed ET
Number of subjects: 234
Study 17167925 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipranavir + ritonavir
Number of subjects: 1159
Study 17167925 — intervention group
Group type: COMPARATOR
Intervention: Other protease inhibitors
Number of subjects: 1159
Study 17167925 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipranavir + ritonavir with enfuvirtide
Number of subjects: 1159
Study 17167925 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipranavir
Number of subjects: 1159
Study 15192250 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk restraint during reach-to-grasp training
Number of subjects: 28
Study 15192250 — intervention group
Group type: COMPARATOR
Intervention: Control group (verbal instruction not to move trunk)
Number of subjects: 28
Study 14516301 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention with monthly audit sessions and outcome feedback for malaria treatment.
Number of subjects: 24
Study 14516301 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention with monthly audit sessions and outcome feedback for diarrhoea treatment.
Number of subjects: 24
Study 14516301 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention with monthly audit sessions and outcome feedback for pneumonia treatment.
Number of subjects: 24
Study 14516301 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention).
Number of subjects: 24
Study 11079651 — intervention group
Group type: EXPERIMENTAL
Intervention: Orbufiban 30 mg, 40 mg, or 50 mg twice daily or 50 mg once daily
Number of subjects: 520
Study 11079651 — intervention group
Group type: EXPERIMENTAL
Intervention: Orbufiban
Number of subjects: 520
Study 11079651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 520
Study 8932852 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib-diphtheria toxoid conjugate vaccine (PRP-D) at 6 months and pneumococcal polysaccharide vaccine (Pnc PS) at 8 months
Number of subjects: 45
Study 8932852 — intervention group
Group type: COMPARATOR
Intervention: Pneumococcal polysaccharide vaccine (Pnc PS) at 18 months and Hib-diphtheria toxoid conjugate vaccine (PRP-D) at 20 months
Number of subjects: 45
Study 1446399 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2.3 mg/kgr
Number of subjects: 20
Study 1446399 — intervention group
Group type: COMPARATOR
Intervention: Thiopental 4.4 mg/kgr
Number of subjects: 20
Study 3997307 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine tablets with rapid absorption
Number of subjects: 9
Study 3997307 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine tablets with slow absorption
Number of subjects: 9
Study 3997307 — intervention group
Group type: COMPARATOR
Intervention: All carbamazepine tablets
Number of subjects: 9
Study 30368036 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-minute de-escalation curriculum for pediatric residents
Number of subjects: 84
Study 30368036 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 84
Study 29370819 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI 100/62.5/25 μg
Number of subjects: 1055
Study 29370819 — intervention group
Group type: COMPARATOR
Intervention: FF/VI + UMEC 100/25 μg + 62.5 μg
Number of subjects: 1055
Study 29370819 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI
Number of subjects: 1055
Study 29370819 — intervention group
Group type: COMPARATOR
Intervention: FF/VI + UMEC
Number of subjects: 1055
Study 25724020 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive psychology intervention (4 personalized positive psychology exercises)
Number of subjects: 96
Study 25724020 — intervention group
Group type: COMPARATOR
Intervention: Control condition (writing about life details for 8 weeks)
Number of subjects: 96
Study 25724020 — intervention group
Group type: EXPERIMENTAL
Intervention: Between-group comparison
Number of subjects: 96
Study 24828020 — intervention group
Group type: EXPERIMENTAL
Intervention: RO-151 200 mg
Number of subjects: 109
Study 24828020 — intervention group
Group type: EXPERIMENTAL
Intervention: RO-838 200 mg
Number of subjects: 109
Study 24828020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 24828020 — intervention group
Group type: EXPERIMENTAL
Intervention: RO-151 5 mg
Number of subjects: 109
Study 24828020 — intervention group
Group type: EXPERIMENTAL
Intervention: RO-838 50 mg
Number of subjects: 109
Study 24828020 — intervention group
Group type: EXPERIMENTAL
Intervention: RO-838
Number of subjects: 109
Study 24828020 — intervention group
Group type: EXPERIMENTAL
Intervention: RO-151
Number of subjects: 109
Study 22841581 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 ppm fluoride in milk
Number of subjects: 23
Study 22841581 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 ppm fluoride in milk
Number of subjects: 23
Study 22841581 — intervention group
Group type: COMPARATOR
Intervention: 0 ppm fluoride in milk (control)
Number of subjects: 23
Study 20207347 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 22
Study 20207347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 18757193 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 Gy boost dose
Number of subjects: 5178
Study 18757193 — intervention group
Group type: COMPARATOR
Intervention: No boost
Number of subjects: 5178
Study 18757193 — intervention group
Group type: EXPERIMENTAL
Intervention: Boost arm with post-operative breast oedema or haematoma
Number of subjects: 5178
Study 18757193 — intervention group
Group type: EXPERIMENTAL
Intervention: Boost arm with WBI given with >6 MV photons
Number of subjects: 5178
Study 18757193 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing maximum whole breast irradiation (WBI) dose
Number of subjects: 5178
Study 18757193 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant chemotherapy
Number of subjects: 5178
Study 18757193 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 5178
Study 15638820 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% fish oil (FO)
Number of subjects: 60
Study 15638820 — intervention group
Group type: COMPARATOR
Intervention: 100% rapeseed oil (RO)
Number of subjects: 60
Study 15638820 — intervention group
Group type: COMPARATOR
Intervention: 50% fish oil / 50% rapeseed oil (FO/RO)
Number of subjects: 60
Study 12050494 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence diagnosis
Number of subjects: 301
Study 12050494 — intervention group
Group type: COMPARATOR
Intervention: White light
Number of subjects: 301
Study 10065579 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg orally
Number of subjects: 11
Study 10065579 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (normal weight)
Number of subjects: 11
Study 7727181 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril plus salicylate
Number of subjects: 20
Study 7727181 — intervention group
Group type: COMPARATOR
Intervention: enalapril plus placebo
Number of subjects: 20
Study 7727181 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril
Number of subjects: 20
Study 7727181 — intervention group
Group type: EXPERIMENTAL
Intervention: salicylate
Number of subjects: 20
Study 2034456 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel lenses with varying water content (36.5% to 85%)
Number of subjects: 6
Study 2034456 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel lenses with higher water content
Number of subjects: 6
Study 2034456 — intervention group
Group type: COMPARATOR
Intervention: Hydrogel lenses
Number of subjects: 6
Study 7307478 — intervention group
Group type: EXPERIMENTAL
Intervention: Social skills training for 10 weeks
Number of subjects: 28
Study 7307478 — intervention group
Group type: COMPARATOR
Intervention: Holistic health therapy plus family therapy for 10 weeks
Number of subjects: 28
Study 29627312 — intervention group
Group type: EXPERIMENTAL
Intervention: Heliox (79:21) delivered via low flow nasal cannula at 2 L/min for 24 hours
Number of subjects: 104
Study 29627312 — intervention group
Group type: COMPARATOR
Intervention: Air delivered via nasal cannula at 2 L/min for 24 hours
Number of subjects: 104
Study 28634710 — intervention group
Group type: EXPERIMENTAL
Intervention: Vuse Solo (14 to 36 mg nicotine)
Number of subjects: 45
Study 28634710 — intervention group
Group type: EXPERIMENTAL
Intervention: Vuse Solo
Number of subjects: 45
Study 28634710 — intervention group
Group type: COMPARATOR
Intervention: Combustible cigarettes
Number of subjects: 45
Study 28634710 — intervention group
Group type: COMPARATOR
Intervention: Nicotine gum
Number of subjects: 45
Study 25370595 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP) 32 mg/day orally for 7 days
Number of subjects: 35
Study 25370595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 23163959 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine (5 mg b.i.d.)
Number of subjects: 120
Study 23163959 — intervention group
Group type: COMPARATOR
Intervention: Levocetirizine (5 mg/day)
Number of subjects: 120
Study 21658525 — intervention group
Group type: EXPERIMENTAL
Intervention: History of traumatic event exposure
Number of subjects: 127
Study 21658525 — intervention group
Group type: COMPARATOR
Intervention: Nonexposed individuals
Number of subjects: 127
Study 21658525 — intervention group
Group type: EXPERIMENTAL
Intervention: Traumatic event exposure
Number of subjects: 127
Study 19455296 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy
Number of subjects: 74
Study 19455296 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Number of subjects: 74
Study 19455296 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (interpersonal psychotherapy plus medication)
Number of subjects: 74
Study 19455296 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 74
Study 17198587 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin-based regimen
Number of subjects: 6478
Study 17198587 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin-based regimen
Number of subjects: 6478
Study 15554350 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 200 mg/day for 3 months
Number of subjects: 30
Study 11261393 — intervention group
Group type: EXPERIMENTAL
Intervention: Homophobic group (n = 26)
Number of subjects: 52
Study 11261393 — intervention group
Group type: COMPARATOR
Intervention: Nonhomophobic group (n = 26)
Number of subjects: 52
Study 11261393 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 52
Study 9492239 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep (measured by time spent awake during NREM-1)
Number of subjects: 29
Study 9492239 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrusive thoughts and avoidance behaviors
Number of subjects: 29
Study 8301447 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemophilus capsular polysaccharide‐tetanus toxoid conjugate (PRP‐T) and diphtheria‐tetanus‐pertussis (DTP) vaccines administered in a single syringe (group 1)
Number of subjects: 284
Study 8301447 — intervention group
Group type: COMPARATOR
Intervention: Haemophilus capsular polysaccharide‐tetanus toxoid conjugate (PRP‐T) and diphtheria‐tetanus‐pertussis (DTP) vaccines administered in separate syringes (group 2)
Number of subjects: 284
Study 8301447 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP‐T vaccine (group 1)
Number of subjects: 284
Study 8301447 — intervention group
Group type: COMPARATOR
Intervention: PRP‐T vaccine (group 2)
Number of subjects: 284
Study 8301447 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP antigens (group 1)
Number of subjects: 284
Study 8301447 — intervention group
Group type: COMPARATOR
Intervention: DTP antigens (group 2)
Number of subjects: 284
Study 2928074 — intervention group
Group type: EXPERIMENTAL
Intervention: 500-Hz low-pass noise adaptor moving right
Number of subjects: 0
Study 2928074 — intervention group
Group type: EXPERIMENTAL
Intervention: 6300-Hz high-pass noise adaptor moving right
Number of subjects: 0
Study 2928074 — intervention group
Group type: EXPERIMENTAL
Intervention: Probes with velocities varying from -10 degrees to +10 degrees/sec
Number of subjects: 0
Study 2928074 — intervention group
Group type: EXPERIMENTAL
Intervention: Same spectral content for adaptor and probe
Number of subjects: 0
Study 2928074 — intervention group
Group type: EXPERIMENTAL
Intervention: Different spectral regions for adaptor and probe
Number of subjects: 0
Study 4174488 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term anticoagulant therapy for one year
Number of subjects: 159
Study 4174488 — intervention group
Group type: COMPARATOR
Intervention: Control group (no long-term anticoagulant therapy)
Number of subjects: 159
Study 380463 — intervention group
Group type: EXPERIMENTAL
Intervention: MR K. pneumoniae infected patients
Number of subjects: 66
Study 380463 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolation techniques
Number of subjects: 66
Study 380463 — intervention group
Group type: COMPARATOR
Intervention: Other gram-negative organisms
Number of subjects: 66
Study 31489525 — intervention group
Group type: EXPERIMENTAL
Intervention: Biobran/MGN-3 (250 mg/day for 3 months)
Number of subjects: 60
Study 31489525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 30799691 — intervention group
Group type: EXPERIMENTAL
Intervention: Tabular fact box with numbers
Number of subjects: 120
Study 30799691 — intervention group
Group type: EXPERIMENTAL
Intervention: Fact box with numbers and icon array
Number of subjects: 120
Study 30799691 — intervention group
Group type: EXPERIMENTAL
Intervention: Fact box with numbers, separate icon arrays, and text
Number of subjects: 120
Study 30799691 — intervention group
Group type: COMPARATOR
Intervention: Widely distributed health information
Number of subjects: 120
Study 29277560 — intervention group
Group type: EXPERIMENTAL
Intervention: Cx601 (120 million allogeneic expanded adipose-derived stem cells)
Number of subjects: 212
Study 29277560 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 212
Study 26927298 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine coronary angiography without a previous non-invasive stress test before PTA
Number of subjects: 450
Study 26927298 — intervention group
Group type: COMPARATOR
Intervention: Selective coronary angiography based on the results of non-invasive stress tests before PTA
Number of subjects: 450
Study 24858657 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (nitrate content 7.5 mmol per 250 ml)
Number of subjects: 27
Study 24858657 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nitrate depleted beetroot juice, nitrate content 0.002 mmol per 250 ml)
Number of subjects: 27
Study 22344613 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 40
Study 22344613 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 40
Study 19056592 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg liquid DHA
Number of subjects: 1160
Study 19056592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1160
Study 17806025 — intervention group
Group type: EXPERIMENTAL
Intervention: Post‐incisional wound infiltration with levobupivacaine 1.25 mg/kg
Number of subjects: 30
Study 17806025 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 30 mg/kg administered rectally
Number of subjects: 30
Study 12969370 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioabsorbable polylactide-polyglycolide acid sponge (Fisiograft)
Number of subjects: 36
Study 12969370 — intervention group
Group type: COMPARATOR
Intervention: Natural healing by clot formation (Control)
Number of subjects: 36
Study 11094004 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (25 mg/24 h)
Number of subjects: 52
Study 11094004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 8720405 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal durotomy during laminoplasty
Number of subjects: 118
Study 8720405 — intervention group
Group type: COMPARATOR
Intervention: Control group (no longitudinal durotomy)
Number of subjects: 118
Study 1357349 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler velocimetry
Number of subjects: 426
Study 1357349 — intervention group
Group type: COMPARATOR
Intervention: CTG
Number of subjects: 426
Study 4004602 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium
Number of subjects: 34
Study 4004602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 31450957 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian trials (283 trials)
Number of subjects: 1020
Study 31450957 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian trials
Number of subjects: 1020
Study 31450957 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian methods for trial design and primary endpoint analysis (75 trials)
Number of subjects: 1020
Study 31450957 — intervention group
Group type: EXPERIMENTAL
Intervention: BATTLE trial
Number of subjects: 1020
Study 31450957 — intervention group
Group type: EXPERIMENTAL
Intervention: I-SPY 2 trial
Number of subjects: 1020
Study 27660289 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein treatment
Number of subjects: 240
Study 27660289 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc, selenium, glutamine, and metoclopramide treatment
Number of subjects: 240
Study 27660289 — intervention group
Group type: EXPERIMENTAL
Intervention: Both nutraceutical strategies
Number of subjects: 240
Study 25567765 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow mononuclear cells (BMMNCs)
Number of subjects: 160
Study 25567765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 22893099 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual cell identification on Robo and Confoscan 4 images
Number of subjects: 82
Study 22893099 — intervention group
Group type: EXPERIMENTAL
Intervention: Confoscan automated cell detection software
Number of subjects: 82
Study 22893099 — intervention group
Group type: EXPERIMENTAL
Intervention: Robo automated cell detection software
Number of subjects: 82
Study 22893099 — intervention group
Group type: EXPERIMENTAL
Intervention: EM‐3000 automated cell detection
Number of subjects: 82
Study 21403038 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive diabetes therapy
Number of subjects: 325
Study 19135567 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mcg of EE and 150 mcg of desogestrel (DSG) for 6 months
Number of subjects: 28
Study 19135567 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mcg of EE and 2 mg of chlormadinone acetate (CMA) for 6 months
Number of subjects: 28